Companies with patented PBS-listed medicines likely now repay more in rebates than they retain in actual payments. To make matters worse, the annual report suggests they may have been repaying more than necessary due to the unconstitutional claiming of PBS benefits for some medicines reimbursed under the Highly Specialised Drugs Program.
Rebates are bad enough without invoices based on unconstitutional benefit claims
November 4, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
Biogen ANZ certified a 'Great Place to Work' for a fifth time
October 16, 2026 - - Latest News -
Tavneos to be withdrawn from Australia as CSL pulls vasculitis treatment
October 16, 2026 - - Latest News -
AI in HTA - survey reveals optimism and concern over a potential missed opportunity
October 16, 2026 - - Latest News -
England's chief scientific officer on the opportunity for Australia to get it right on genomics
October 15, 2026 - - Latest News -
The medicines gap costing Australian children time they can't get back
October 15, 2026 - - Latest News -
Brain cancer advocates return to Canberra 'to keep that ambition alive'
October 15, 2026 - - Latest News -
The effort to change an institution from within, works best when exit is possible
October 15, 2026 - - Latest News
